Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Etrasimod shows therapeutic potential in ulcerative colitis

13 Dec 2019

Treatment with etrasimod 2 mg yields clinical and endoscopic improvements in patients with moderately to severely active ulcerative colitis (UC), according to the results of a phase II trial.

The trial randomized 156 adult UC outpatients with modified Mayo Clinic scores (MCSs) of 4–9, endoscopic subscores of 2, and rectal bleeding subscores of ≥1 to receive 12 weeks of treatment with once-daily etrasimod 1 mg (n=52), etrasimod 2 mg (n=50), or placebo (n=54).

At week 12, the primary endpoint of mean improvement in modified MCS from baseline was significantly greater with the active drug at the higher but not at the lower dose vs placebo. Specifically, scores in the 2-mg and 1-mg dose groups were higher by 99 points (90 percent confidence interval [CI], 0.30–1.68; p=0.009) and 0.43 points (90 percent CI, –0.24 to 1.11; p=0.15), respectively, than in the placebo group.

Likewise, the difference in the number of patients who achieved endoscopic remission was significant only in the higher-dose etrasimod group vs placebo (difference vs placebo; 2 mg: 24.4 percent, 90 percent CI, 9.8–39.0; p=0.003; 1 mg: 4.1 percent, 90 percent CI, −9.1 to 17.2; p=0.31).

Most adverse events were mild to moderate in severity. There were three patients who developed a transient, asymptomatic, low-grade atrioventricular block that resolved spontaneously and did not recur with further dosing; the two patients had evidence of atrioventricular block prior to etrasimod exposure.

Further clinical development of etrasimod for UC is warranted, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.